Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Faron updated its research and financing plans

FARONAnalyst Comment12.02.2026 klo 10.24
Antti SiltanenAnalyst
Discuss

Summary

  • Faron updated its research and financing plans, including a planned 40 MEUR share issue, with key terms expected to be clarified soon.
  • The company revised its trial plan for high-risk myelodysplastic syndrome, moving to a traditional two-phase model due to a partner withdrawal after negative Phase III VERONA study results.
  • The new trial plan involves fewer patients, reducing costs but also statistical power, with complete remission and duration of response proposed as primary endpoints to the FDA.
  • The market is disappointed with the equity financing plan, leading to a sharp decline in Faron's share price, increasing risks associated with the planned rights issue.

This content is generated by AI. You can give feedback on it in the Inderes forum.

Translation: Original published in Finnish on 02/12/2026 at 07:49 am EET

Faron updated its business plans, and the related webcast can be viewed here. We interviewed management about updated research plans and the planned share issue of 40 MEUR. From the perspective of the stock's valuation, the next key milestone is the clarification of the terms of the upcoming share issue, which we expect in the near future. We will update our research when key information is available.

Updates to the registration trial plan, but the framework remains unchanged

The company previously planned a continuous Phase II/III trial in high-risk myelodysplastic syndrome (HR-MDS) as a first-line treatment. According to the company, plans changed following discussions at the American Society of Hematology (ASH) conference in December. According to Faron, they had an advanced understanding of a partnership with a larger pharmaceutical company, but the potential partner withdrew from the project based on the results of the Phase III VERONA study presented at the meeting. In VERONA, the combination of the BCL2 inhibitor venetoclax and azacitidine was compared to azacitidine alone. Due to the negative results, Faron changed its plans for the structure of the future trial, and the project's financing plan shifted to rely on equity financing. The new plan is based on a more traditional two-phase model, where Phases II and III are separate.

According to the new plan, the company intends to first conduct a Phase II study with 90 patients in three groups of 30 (a control group and two different dosage groups of bex+aza). The previous plan was for 3x40 patients, meaning the planned number of patients is one-quarter lower than before. This limits both Faron's costs and the statistical power of the study, i.e., the probability of achieving a statistically significant difference between the treatment and control groups. Faron plans to propose the use of complete remission (CR) combined with duration of response as the primary endpoint for the study to the FDA. This is in line with the FDA's guidance issued at the end of 2025. In addition, a potential primary endpoint could be progression-free survival. Overall survival would thus be left out. If realized, the strength of the new plan is a smaller number of patients and faster throughput, as the patient follow-up period is shortened. Naturally, the costs would also be lower. In our opinion, the risk caused by the smaller number of early-stage patients, where potential differences between groups may not emerge due to weaker statistical power, is a deterioration from the previous situation.

Significant financing effort ahead

The planned rights issue of 40 MEUR is a significant effort for Faron. The market has been expecting the financing of further research through a partnership agreement. The company has also fueled these expectations with its communication. The market has been very disappointed with the issue-based financing plans, as a result of which the share price has fallen sharply. This increases the likelihood of an issue being carried out at a low share price, which would further significantly increase the number of shares. The share price decline also means a larger increase in the number of shares than previously estimated through the conversion of the bond. Financing, therefore, involves significant risks. However, Faron presented alternative plans for how the company can advance its goals even if the funding round falls short. Successfully raising the targeted amount in the issue would be crucial for the company to ensure the advancement of its research program. We expect the terms of the offering to be finalized in the coming weeks and will update our estimates once additional essential information becomes available.

 

Login required

This content is only available for logged in users

Create account

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more on company page

Key Estimate Figures10.02.

202425e26e
Revenue0.00.00.0
growth-%
EBIT (adj.)-18.7-22.6-30.5
EBIT-% (adj.)-466,750.0 %-565,225.0 %-762,390.0 %
EPS (adj.)-0.24-0.15-0.19
Dividend0.000.000.00
Dividend %
P/E (adj.)neg.neg.neg.
EV/EBITDAneg.neg.neg.

Forum discussions

Thanks! Based on the share count, I assume HCM belongs to that Investment Advisor segment. Additionally, under AIM rules, notifications must...
32 minutes ago
by Tuul1puku
0
Unless I’ve missed something, that’s not the case. A completely normal repayment is due in December. The early October repayment was postponed...
20 hours ago
by OsakasOssi
7
Wasn’t it so that in December Faron only pays interest to HCM, a bit over 160,000 euros, and the next principal repayment is in February 2027...
20 hours ago
by Samuel Benner
1
The Investment Advisor segment hasn’t changed at all. 63 retail investors have joined, 3 corporate owners have exited, but not with a significant...
21 hours ago
by OsakasOssi
2
And BEXERA’s estimated start date has been moved forward by a month (which is positive in itself if it already starts this month). Primary Completion...
11/13/2026, 5:39 PM
by jukkamu
13
BEXERA has opened three new recruitment sites: clinicaltrials.gov ClinicalTrials.gov Duarte, California, United States, 91010 Recruiting City...
11/13/2026, 4:23 PM
by Kulkuri
25
A recent, not yet peer-reviewed study from Helsinki on pediatric cancers (neuroblastoma). Among other things, Clever-1 was detected in them....
11/13/2026, 3:40 PM
by Kulkuri
10